Calculation of proportional impairment ratio for objective tests by dose.

Adjusted and unadjusted hazard ratio (HR) for all-cause mortality by subgroups by trial vaccination.

Ruud Andreas Fritz Verhees (6729545)
Carel Thijs (112720)
Ton Ambergen (295464)
Geert Jan Dinant (716561)
Johannes Andreas Knottnerus (6729548)

May 2019

Adjusted and unadjusted hazard ratio (HR) for all-cause mortality by subgroups by trial vaccination....

Disproportionality analysis for antihistamines with cases of cardiac arrest (CA) or sudden cardiac death (SCD).

Elisabetta Poluzzi (487411)
Emanuel Raschi (487410)
Brian Godman (487412)
Ariola Koci (487413)
Ugo Moretti (487414)
Marija Kalaba (487415)
Bjorn Wettermark (487417)
Miriam Sturkenboom (408749)
Fabrizio De Ponti (487418)

March 2015

NOTES: in italic, not statistically significant ROR; na = number of cases <3Disproportiona...

Number of vaccine doses administered and median interval of TBE occurrence in any patient with TBE who had received at least one TBE vaccine dose.

Dace Zavadska (2817451)
Zane Odzelevica (5959049)
Guntis Karelis (5959052)
Lelde Liepina (5959055)
Zane Anna Litauniece (5959058)
Antra Bormane (74869)
Irina Lucenko (5959061)
Jurijs Perevoscikovs (5959064)
Linda Bridina (5959067)
Laura Veide (5959070)
Angelika Krumina (3560147)
Jelena Storozenko (5959073)
Wilhelm Erber (5959076)
Myint Tin Tin Htar (4042883)
Heinz-Josef Schmitt (4042892)

November 2018

Number of vaccine doses administered and median interval of TBE occurrence in any patient with TBE w...

Calculation of proportional impairment ratio for subjective tests for the second-generation antihistamines in Japan.

Tatsuya Isomura (548724)
Takeshi Kono (674097)
Ian Hindmarch (674098)
Norimasa Kikuchi (462989)
Aya Murakami (432768)
Kyoko Inuzuka (548725)
Seiji Kawana (674099)

December 2014

a: Number of tests showing ‘impairment’ with the named antihistamine (AH). b: Number of tests sho...

Proportional impairment ratio calculation formula for an antihistamine.

Tatsuya Isomura (548724)
Takeshi Kono (674097)
Ian Hindmarch (674098)
Norimasa Kikuchi (462989)
Aya Murakami (432768)
Kyoko Inuzuka (548725)
Seiji Kawana (674099)

December 2014

a: Number of tests showing ‘impairment’ with the named antihistamine (AH). b: Number of tests sho...

Number of test results showing impairment and no impairment for each AH by dose.

Tatsuya Isomura (548724)
Takeshi Kono (674097)
Ian Hindmarch (674098)
Norimasa Kikuchi (462989)
Aya Murakami (432768)
Kyoko Inuzuka (548725)
Seiji Kawana (674099)

December 2014

Number of test results showing impairment and no impairment for each AH by dose.</p

Percentage (Number) of doses relative to each discrete dose scheme which are optimal doses based on the optimal toxicity interval (θ ± 0.10).

Márcio Augusto Diniz (6191303)
Mourad Tighiouart (243703)
André Rogatko (5658436)

January 2019

Percentage (Number) of doses relative to each discrete dose scheme which are optimal doses based on ...

Central Nervous System Effects of the Second-Generation Antihistamines Marketed in Japan -Review of Inter-Drug Differences Using the Proportional Impairment Ratio (PIR)-

Tatsuya Isomura (548724)
Takeshi Kono (674097)
Ian Hindmarch (674098)
Norimasa Kikuchi (462989)
Aya Murakami (432768)
Kyoko Inuzuka (548725)
Seiji Kawana (674099)

December 2014

<div>BackgroundSecond-generation antihistamines (AHs) have, in general, fewer sedative eff...

Percentage (Number) of doses relative to each discrete dose scheme which are optimal doses based on the optimal MTD interval (True MTD ± 0.15 × True MTD).

Márcio Augusto Diniz (6191303)
Mourad Tighiouart (243703)
André Rogatko (5658436)

January 2019

Percentage (Number) of doses relative to each discrete dose scheme which are optimal doses based on ...

The frequency of acute toxicities for the three groups [No. of patient (%)].

Jianshe Wang (730385)
Junnian Zheng (283838)
Tianyou Tang (730386)
Feng Zhu (685)
Yuanhu Yao (730387)
Jing Xu (15337)
Andrew Z. Wang (730388)
Longzhen Zhang (730389)

April 2015

The frequency of acute toxicities for the three groups [No. of patient (%)].</p

Number of diseased subjects recruited in control sample (A); Ratio of upper and lower bound of 95% confidence intervals of prevalence odds (B), in a case-base study of 200 distinct subjects (solid lines), 2000 distinct subjects (dashed lines) and 20000 distinct subjects (dotted lines).

Tina Tsz-Ting Chui (496929)
Wen-Chung Lee (73587)

December 2013

Number of diseased subjects recruited in control sample (A); Ratio of upper and lower bound of 95...

Values of infection-related quantities of nine patients based on median estimates of parameters and 95% credible intervals.

Carolin Vegvari (516405)
Christoforos Hadjichrysanthou (3159321)
Emilie Cauët (2533993)
Emma Lawrence (265291)
Anne Cori (260622)
Frank de Wolf (89583)
Roy M. Anderson (230318)

July 2016

Values of infection-related quantities of nine patients based on median estimates of parameters a...

Proportions of antibiotic choice congruence to DEGAM guideline for acute lower respiratory tract infection by diagnosis.

Eva Maria Kraus (3873898)
Steffen Pelzl (3873901)
Joachim Szecsenyi (14931)
Gunter Laux (72577)

March 2017

Proportions of antibiotic choice congruence to DEGAM guideline for acute lower respiratory tract ...

Sensitivity analysis of clinical cure rates, microbiological eradication rates and adverse events rates.

Yang Peng (486260)
Xiaohua Ye (381307)
Ying Li (38224)
Tao Bu (486261)
Xiaofeng Chen (392939)
Jiaqi Bi (486262)
Junli Zhou (131029)
Zhenjiang Yao (486263)

November 2013

Results were computed by omitting each study in turn. The two ends of the dotted lines represent ...

HPV 31/33/45: Prevalence ratio employed for calculating direct, indirect, total and overall effectiveness.

M. Jesus Purriños-Hermida (5593646)
María Isolina Santiago-Pérez (5593649)
Mercedes Treviño (5593652)
Rafaela Dopazo (5593655)
Angelina Cañizares (667514)
Isolina Bonacho (5593658)
Matilde Trigo (830322)
M. Eva Fernández (5593661)
Ana Cid (612956)
David Gómez (5593664)
Patricia Ordóñez (830317)
Amparo Coira (5593667)
M. J. Armada (5593670)
Magdalena Porto (5593673)
Sonia Perez (3460616)
Alberto Malvar-Pintos (5593676)

August 2018

HPV 31/33/45: Prevalence ratio employed for calculating direct, indirect, total and overall effec...

Adjusted and unadjusted hazard ratio (HR) for all-cause mortality by subgroups by trial vaccination.

Ruud Andreas Fritz Verhees (6729545)
Carel Thijs (112720)
Ton Ambergen (295464)
Geert Jan Dinant (716561)
Johannes Andreas Knottnerus (6729548)

May 2019

Adjusted and unadjusted hazard ratio (HR) for all-cause mortality by subgroups by trial vaccination....

Disproportionality analysis for antihistamines with cases of cardiac arrest (CA) or sudden cardiac death (SCD).

Elisabetta Poluzzi (487411)
Emanuel Raschi (487410)
Brian Godman (487412)
Ariola Koci (487413)
Ugo Moretti (487414)
Marija Kalaba (487415)
Bjorn Wettermark (487417)
Miriam Sturkenboom (408749)
Fabrizio De Ponti (487418)

March 2015

NOTES: in italic, not statistically significant ROR; na = number of cases <3Disproportiona...

Number of vaccine doses administered and median interval of TBE occurrence in any patient with TBE who had received at least one TBE vaccine dose.

Dace Zavadska (2817451)
Zane Odzelevica (5959049)
Guntis Karelis (5959052)
Lelde Liepina (5959055)
Zane Anna Litauniece (5959058)
Antra Bormane (74869)
Irina Lucenko (5959061)
Jurijs Perevoscikovs (5959064)
Linda Bridina (5959067)
Laura Veide (5959070)
Angelika Krumina (3560147)
Jelena Storozenko (5959073)
Wilhelm Erber (5959076)
Myint Tin Tin Htar (4042883)
Heinz-Josef Schmitt (4042892)

November 2018

Number of vaccine doses administered and median interval of TBE occurrence in any patient with TBE w...

Calculation of proportional impairment ratio for subjective tests for the second-generation antihistamines in Japan.

Tatsuya Isomura (548724)
Takeshi Kono (674097)
Ian Hindmarch (674098)
Norimasa Kikuchi (462989)
Aya Murakami (432768)
Kyoko Inuzuka (548725)
Seiji Kawana (674099)

December 2014

a: Number of tests showing ‘impairment’ with the named antihistamine (AH). b: Number of tests sho...

Proportional impairment ratio calculation formula for an antihistamine.

Tatsuya Isomura (548724)
Takeshi Kono (674097)
Ian Hindmarch (674098)
Norimasa Kikuchi (462989)
Aya Murakami (432768)
Kyoko Inuzuka (548725)
Seiji Kawana (674099)

December 2014

a: Number of tests showing ‘impairment’ with the named antihistamine (AH). b: Number of tests sho...

Number of test results showing impairment and no impairment for each AH by dose.

Tatsuya Isomura (548724)
Takeshi Kono (674097)
Ian Hindmarch (674098)
Norimasa Kikuchi (462989)
Aya Murakami (432768)
Kyoko Inuzuka (548725)
Seiji Kawana (674099)

December 2014

Number of test results showing impairment and no impairment for each AH by dose.</p

Percentage (Number) of doses relative to each discrete dose scheme which are optimal doses based on the optimal toxicity interval (θ ± 0.10).

Márcio Augusto Diniz (6191303)
Mourad Tighiouart (243703)
André Rogatko (5658436)

January 2019

Percentage (Number) of doses relative to each discrete dose scheme which are optimal doses based on ...

Central Nervous System Effects of the Second-Generation Antihistamines Marketed in Japan -Review of Inter-Drug Differences Using the Proportional Impairment Ratio (PIR)-

Tatsuya Isomura (548724)
Takeshi Kono (674097)
Ian Hindmarch (674098)
Norimasa Kikuchi (462989)
Aya Murakami (432768)
Kyoko Inuzuka (548725)
Seiji Kawana (674099)

December 2014

<div>BackgroundSecond-generation antihistamines (AHs) have, in general, fewer sedative eff...

Percentage (Number) of doses relative to each discrete dose scheme which are optimal doses based on the optimal MTD interval (True MTD ± 0.15 × True MTD).

Márcio Augusto Diniz (6191303)
Mourad Tighiouart (243703)
André Rogatko (5658436)

January 2019

Percentage (Number) of doses relative to each discrete dose scheme which are optimal doses based on ...

The frequency of acute toxicities for the three groups [No. of patient (%)].

Jianshe Wang (730385)
Junnian Zheng (283838)
Tianyou Tang (730386)
Feng Zhu (685)
Yuanhu Yao (730387)
Jing Xu (15337)
Andrew Z. Wang (730388)
Longzhen Zhang (730389)

April 2015

The frequency of acute toxicities for the three groups [No. of patient (%)].</p

Number of diseased subjects recruited in control sample (A); Ratio of upper and lower bound of 95% confidence intervals of prevalence odds (B), in a case-base study of 200 distinct subjects (solid lines), 2000 distinct subjects (dashed lines) and 20000 distinct subjects (dotted lines).

Tina Tsz-Ting Chui (496929)
Wen-Chung Lee (73587)

December 2013

Number of diseased subjects recruited in control sample (A); Ratio of upper and lower bound of 95...

Values of infection-related quantities of nine patients based on median estimates of parameters and 95% credible intervals.

Carolin Vegvari (516405)
Christoforos Hadjichrysanthou (3159321)
Emilie Cauët (2533993)
Emma Lawrence (265291)
Anne Cori (260622)
Frank de Wolf (89583)
Roy M. Anderson (230318)

July 2016

Values of infection-related quantities of nine patients based on median estimates of parameters a...

Proportions of antibiotic choice congruence to DEGAM guideline for acute lower respiratory tract infection by diagnosis.

Eva Maria Kraus (3873898)
Steffen Pelzl (3873901)
Joachim Szecsenyi (14931)
Gunter Laux (72577)

March 2017

Proportions of antibiotic choice congruence to DEGAM guideline for acute lower respiratory tract ...

Sensitivity analysis of clinical cure rates, microbiological eradication rates and adverse events rates.

Yang Peng (486260)
Xiaohua Ye (381307)
Ying Li (38224)
Tao Bu (486261)
Xiaofeng Chen (392939)
Jiaqi Bi (486262)
Junli Zhou (131029)
Zhenjiang Yao (486263)

November 2013

Results were computed by omitting each study in turn. The two ends of the dotted lines represent ...

HPV 31/33/45: Prevalence ratio employed for calculating direct, indirect, total and overall effectiveness.

M. Jesus Purriños-Hermida (5593646)
María Isolina Santiago-Pérez (5593649)
Mercedes Treviño (5593652)
Rafaela Dopazo (5593655)
Angelina Cañizares (667514)
Isolina Bonacho (5593658)
Matilde Trigo (830322)
M. Eva Fernández (5593661)
Ana Cid (612956)
David Gómez (5593664)
Patricia Ordóñez (830317)
Amparo Coira (5593667)
M. J. Armada (5593670)
Magdalena Porto (5593673)
Sonia Perez (3460616)
Alberto Malvar-Pintos (5593676)

August 2018

HPV 31/33/45: Prevalence ratio employed for calculating direct, indirect, total and overall effec...

Adjusted and unadjusted hazard ratio (HR) for all-cause mortality by subgroups by trial vaccination.

Ruud Andreas Fritz Verhees (6729545)
Carel Thijs (112720)
Ton Ambergen (295464)
Geert Jan Dinant (716561)
Johannes Andreas Knottnerus (6729548)

May 2019

Adjusted and unadjusted hazard ratio (HR) for all-cause mortality by subgroups by trial vaccination....

Disproportionality analysis for antihistamines with cases of cardiac arrest (CA) or sudden cardiac death (SCD).

Elisabetta Poluzzi (487411)
Emanuel Raschi (487410)
Brian Godman (487412)
Ariola Koci (487413)
Ugo Moretti (487414)
Marija Kalaba (487415)
Bjorn Wettermark (487417)
Miriam Sturkenboom (408749)
Fabrizio De Ponti (487418)

March 2015

NOTES: in italic, not statistically significant ROR; na = number of cases <3Disproportiona...

Number of vaccine doses administered and median interval of TBE occurrence in any patient with TBE who had received at least one TBE vaccine dose.

Dace Zavadska (2817451)
Zane Odzelevica (5959049)
Guntis Karelis (5959052)
Lelde Liepina (5959055)
Zane Anna Litauniece (5959058)
Antra Bormane (74869)
Irina Lucenko (5959061)
Jurijs Perevoscikovs (5959064)
Linda Bridina (5959067)
Laura Veide (5959070)
Angelika Krumina (3560147)
Jelena Storozenko (5959073)
Wilhelm Erber (5959076)
Myint Tin Tin Htar (4042883)
Heinz-Josef Schmitt (4042892)

November 2018

Number of vaccine doses administered and median interval of TBE occurrence in any patient with TBE w...

Calculation of proportional impairment ratio for objective tests by dose.

Abstract

Extracted data

Calculation of proportional impairment ratio for objective tests by dose.

Abstract

Extracted data

Related items

Related items